Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacitracin is a polypeptide antibiotic primarily used topically to prevent infection in minor skin injuries such as cuts, scrapes, and burns. It is produced by *Bacillus licheniformis* and consists of a mixture of related cyclic peptides, with bacitracin A being the most active component. Bacitracin works by inhibiting bacterial cell wall synthesis through interference with the dephosphorylation of C55-isoprenyl pyrophosphate, an essential molecule in peptidoglycan biosynthesis. This action disrupts the formation of the bacterial cell wall, leading to bacteriostatic or bactericidal effects against Gram-positive bacteria. Systemic use (intramuscular) is rare due to nephrotoxicity but may be considered for specific staphylococcal infections in infants[1][2][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bacitracin.